Marc J. Pliskin

PD23-15 SAFETY OF RUCAPARIB VS DOCETAXEL OR SECOND-GENERATION ANDROGEN RECEPTOR PATHWAY INHIBITOR THERAPY FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND A BRCA MUTATION IN TRITON3

Joel R. Gingerich, Alan Haruo Bryce, Karim Fizazi, Charles J. Ryan et autres

PD23-05 DURATION OF TREATMENT SUSPENSION AMONG ALL RANDOMIZED PATIENTS IN EMBARK

Neal D. Shore, Paul R. Sieber, Ugo De Giorgi, Daniel Costin Danila et autres

IP43-19 LARGE-SCALE, PROSPECTIVE, CLINICAL VALIDATION STUDY OF THE DIAGNOSTIC PERFORMANCE OF ISOPSA® WITHOUT AND IN COMBINATION WITH MULTI-PARAMETRIC MRI FOR THE DETECTION OF HIGH- GRADE PROSTATE CANCER

Aaron Milbank, Matthew D. Truesdale, Lawrence Belkoff, Paul E. Dato et autres

IP21-27 IsoPSA LARGE SCALE PROSPECTIVE VALIDATION STUDY: PERFORMANCE OF THE IsoPSA TEST IN PATIENTS AGED 50-69 YEARS

AARON J. MILBANK, Lawrence Belkoff, Paul E. Dato, Sheldon J. Freedman et autres

Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.

Neal D. Shore, PAUL R. SIEBER, Martin Edwin Gleave, Ugo De Giorgi et autres

15 Background: In the 3-arm EMBARK trial, enzalutamide (enza) + leuprolide acetate (leuprolide) and enza monotherapy (mono) showed statistically superior and clinically meaningful improvements in metastasis-free survival (MFS) vs placebo + leuprolide (alone) in patients (pts) with high-risk biochemically recurrent (BCR) prostate …

us, ca, it (code pays fourni par la source)

Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.

Stephen J. Freedland, PAUL R. SIEBER, Martin Edwin Gleave, Ugo De Giorgi et autres

156 Background: The 3-arm EMBARK trial found statistically superior and clinically meaningful improvements in metastasis-free survival (MFS) with enzalutamide + leuprolide acetate (enza combo) and enza monotherapy vs placebo + leuprolide (alone) in patients (pts) with high-risk BCR prostate cancer. Tx was …

us, ca, it (code pays fourni par la source)

Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study

Neal D. Shore, Karim S. Fizazi, Teuvo L.J. Tammela, Murilo de Almeida Luz et autres

BACKGROUND: In the phase 3 ARAMIS study (NCT02200614), darolutamide significantly improved metastasis-free survival in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Following the primary analysis, the study was unblinded, and placebo recipients were permitted to cross over to open-label darolutamide. Despite crossover, …

us, fr, fi, br, pe, ca, co, de (code pays fourni par la source)

IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study

Jason Scovell, Mark Stovsky, Alan Wayne Partin, Yair Lotan et autres

OBJECTIVE: To. determine the impact of 5-α reductase inhibitors or α-blockers on IsoPSA performance for the detection of actionable prostate cancer. MATERIALS AND METHODS: This is a secondary analysis of data from an institutional review board approved, prospective, multicenter(8-sites) study evaluating IsoPSA …

us, il (code pays fourni par la source)

Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study

Eric A. Klein, Alan Wayne Partin, Yair Lotan, Jack Baniel et autres

BACKGROUND: IsoPSA is a blood-based test that assesses prostate cancer (CaP) risk by partitioning and detecting cancer-specific structural isoforms of prostate specific antigen (PSA) with an aqueous 2- phase system. OBJECTIVE: To validate the diagnostic performance of IsoPSA for High-Grade CaP and …

us, il (code pays fourni par la source)

MP60-03 ISOPSA: CLINICAL PERFORMANCE OF A SINGLE PARAMETER, STRUCTURE BASED TEST FOR HIGH GRADE PROSTATE CANCER IN A LARGE, MULTICENTER, PROSPECTIVE VALIDATION TRIAL

Eric W. Klein, Alan Wayne Partin, Yair Lotan, Jack Baniel et autres

You have accessJournal of UrologyProstate Cancer: Markers (MP60)1 Sep 2021MP60-03 ISOPSA: CLINICAL PERFORMANCE OF A SINGLE PARAMETER, STRUCTURE BASED TEST FOR HIGH GRADE PROSTATE CANCER IN A LARGE, MULTICENTER, PROSPECTIVE VALIDATION TRIAL Eric Klein, Alan Partin, Yair Lotan, Jack Baniel, Martin Dineen, …

Reply by Authors

Kevin T. McVary, MARC C. GITTELMAN, Kenneth A. Goldberg, Kalpesh Patel et autres

No AccessJournal of UrologyAdult Urology1 Sep 2021Reply by Authorsis a reply to letterEditorial CommentEditorial Comment Kevin T. McVary, Marc C. Gittelman, Kenneth A. Goldberg, Kalpesh Patel, Neal D. Shore, Richard M. Levin, Marc Pliskin, J. Randolf Beahrs, David Prall, Jed Kaminetsky, Barrett …

us (code pays fourni par la source)

Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Kevin T. McVary, MARC C. GITTELMAN, Kenneth A. Goldberg, Kalpesh Patel et autres

PURPOSE: We present final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor therapy (Rezūm™) for treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia. MATERIALS AND METHODS: 50 years of age with International …

us (code pays fourni par la source)